Category: W.L. Gore & Associates
W.L. Gore's newly approved drug-coated Viabahn stent graft beat the current standard of care in treating patients with stenoses or thrombotic occlusions, according to the REVISE clinical study findings.
Arizona medical device maker W.L. Gore & Assoc. teased positive results from its REVISE clinical trial, promising to release additional findings during the American Society of Diagnostic & Interventional Nephrology meeting in Phoenix this week.
C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.
A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.
W.L. Gore enrolls its 1st patient in the Gore TAG thoracic branch endoprosthesis LSA feasibility study in the U.S.
W.L. Gore & Associates enrolled the 1st patient in its U.S. Gore TAG thoracic branch endoprosthesis LSA feasibility study in hopes of landing FDA approval for treatment of thoracic aortic aneurysms in the left subclavian artery.
W.L. Gore & Assoc. appeals its $860 million patent infringement loss to C.R. Bard over stent graft technology.
C.R. Bard (NYSE:BCR) had no standing to bring the patent infringement lawsuit that won it a nearly $860 million verdict against W.L. Gore & Assoc., Gore argued in its appeal yesterday.
W.L. Gore touts expanded approval to market its Viabahn endoprosthesis to treat stenosis and thrombosis in synthetic vascular access grafts.
W.L. Gore & Associates today touted expanded FDA approval for its Viabahn endoprosthesis, now indicated for treatment of stenosis and thrombotic occlusions related to synthetic vascular access grafts.
W.L. Gore & Associates lands Japanese approval for its Excluder AAA endoprosthesis with the C3 delivery system.
W.L. Gore & Associates said it won Shonin approval from the Japanese Ministry of Health, Labor & Welfare to market its Excluder AAA endoprosthesis with C3 delivery system for treatment of abdominal aortic aneurysms.
Gore's enrolls the 1st patient in a clinical trial of its Excluder iliac branch devices in treatment of patients with common iliac artery aneurysms.
W.L. Gore & Associates this week enrolled its 1st patient in a study of its Excluder iliac branch devices, evaluating the implants in treatment of common iliac artery aneurysms or aorto-iliac aneurysms.